Investment
Features
FeesSafety
Academy
More
Pluang+

Compare iShares MSCI Indonesia ETF (EIDO) vs Revvity Inc (RVTY) Price & Performance

iShares MSCI Indonesia ETFTrade
Revvity IncTrade

Price performance (Past 24H)

Key statistics

iShares MSCI Indonesia ETF vs Revvity Inc — how do they compare? iShares MSCI Indonesia ETF trades at $12.69, while Revvity Inc trades at $116.53 (market cap $12.91B). The key difference: Revvity Inc pays a 0.24% dividend while iShares MSCI Indonesia ETF pays none, and Revvity Inc is trading nearer its 52-week high, iShares MSCI Indonesia ETF nearer its low. Which is the better fit depends on your goals.

EIDORVTY
52-Week High
$19.22$117.75
52-Week Low
$10.80$82.26
Market Cap
$12.91B
Sector
Technology
Enterprise Value
$15.23B
Dividend Yield
0.24%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

iShares MSCI Indonesia ETF

EIDO, the iShares MSCI Indonesia ETF, trades at $12.675, down 0.59% today, with a bearish technical signal from moving averages. The fund's valuation appears low, but financial data for the current period is unavailable. Recent news highlights Indonesia's economic initiatives and central bank policy shifts, while technical indicators show neutral oscillators and defined support at $12.

The outlook is mixed, with potential from Indonesia's GDP growth initiatives but weighed by foreign capital outflows and a strong financials weighting. Risks include currency volatility and dependence on commodity markets. Analyst sentiment is neutral due to weak price action despite attractive valuations.

Revvity Inc

RVTY trades at $116.10, up 0.07% on the day, with a bullish technical signal and strong earnings beats in recent quarters. The company reported Q2 2026 EPS of $1.41, surpassing the $1.21 estimate, and raised its full-year outlook due to robust diagnostics demand. Revenue remains steady around $2.9 billion, with a net income margin of 8.16%. Analyst consensus is a Buy with a $120.50 price target, and recent news highlights product launches like the SuperFlex prenatal system and high-throughput TB testing platform.

The outlook for RVTY is positive, supported by earnings momentum and strategic innovations, but investors face risks from high valuation multiples and competitive pressures in the healthcare sector. The stock's proximity to its consensus target suggests limited near-term upside, requiring careful monitoring of execution against raised guidance.

Returns comparison

Trailing returns across standard periods

About iShares MSCI Indonesia ETF

The fund generally will invest at least 80% of its assets in the component securities of the underlying index and in investments that have economic characteristics that are substantially identical to the component securities of the underlying index. The index is a free float-adjusted market capitalization-weighted index that is designed to measure the performance of the large-, mid- and small-capitalization segments of the equity market in Indonesia. The fund is non-diversified.

Read more on EIDO

About Revvity Inc

Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.

Read more on RVTY